Whitehawk Therapeutics, Inc.
WHWKFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Whitehawk Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Whitehawk Therapeutics, Inc. — 10-K filed Mar 12, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 10 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 15, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 2026-03-31 | 4,166,000 | $14.4M | SEC filing |
| Hudson Bay Capital Management LP | 2026-03-31 | 57,597 | $199K | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 121 | $397 | SEC filing |
| Ally Bridge Group (NY) LLC | 2026-03-31 | 817,939 | $2.82M | SEC filing |
| Woodline Partners LP | 2026-03-31 | 281,497 | $971K | SEC filing |
| JANE STREET GROUP, LLC | 2026-03-31 | 151,110 | $521K | SEC filing |
| BARCLAYS PLC | 2026-03-31 | 647 | $2.23K | SEC filing |
| SBI Securities Co., Ltd. | 2026-03-31 | 23 | $79 | SEC filing |
| Russell Investments Group, Ltd. | 2026-03-31 | 386 | $1.33K | SEC filing |
| Verdad Advisers, LP | 2026-03-31 | 115,484 | $398K | SEC filing |
| XTX Topco Ltd | 2026-03-31 | 22,983 | $79.3K | SEC filing |
| Brevan Howard Capital Management LP | 2026-03-31 | 12,589 | $43.4K | SEC filing |
| STATE STREET CORP | 2026-03-31 | 160,382 | $553K | SEC filing |
| OMERS ADMINISTRATION Corp | 2026-03-31 | 11,500 | $39.7K | SEC filing |
| Yu Fan | 2026-03-31 | 2,070,000 | $7.14M | SEC filing |
| Seven Fleet Capital Management LP | 2026-03-31 | 54,296 | $187K | SEC filing |
| Parallel Advisors, LLC | 2026-03-31 | 8 | $28 | SEC filing |
| BARTLETT & CO. WEALTH MANAGEMENT LLC | 2026-03-31 | 1,333 | $5.55K | SEC filing |
| CWM, LLC | 2026-03-31 | 25 | $86 | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2026-03-31 | 203,465 | $702K | SEC filing |
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- BlackRock, Inc.: 299,011 shares reported 2025-12-31; 351,385 shares reported 2026-03-31.
- BANK OF AMERICA CORP /DE/: 411 shares reported 2025-12-31; 52,861 shares reported 2026-03-31.
- QVT Financial LP: 4,615,709 shares reported 2025-12-31; 4,615,709 shares reported 2026-03-31.
- BNP PARIBAS FINANCIAL MARKETS: 160 shares reported 2025-12-31; 202 shares reported 2026-03-31.
- GEODE CAPITAL MANAGEMENT, LLC: 425,440 shares reported 2025-12-31; 457,540 shares reported 2026-03-31.
- US BANCORP \DE\: 3,333 shares reported 2025-12-31; 3,333 shares reported 2026-03-31.
- RENAISSANCE TECHNOLOGIES LLC: 440,722 shares reported 2025-12-31; 428,622 shares reported 2026-03-31.
- Eversept Partners, LP: 260,259 shares reported 2025-12-31; 306,800 shares reported 2026-03-31.
- PRELUDE CAPITAL MANAGEMENT, LLC: 18,796 shares reported 2025-12-31; 10,283 shares reported 2026-03-31.
- ACADIAN ASSET MANAGEMENT LLC: 24,634 shares reported 2025-12-31; 70,101 shares reported 2026-03-31.
- UBS Group AG: 29,844 shares reported 2025-12-31; 11,438 shares reported 2026-03-31.
- CITADEL ADVISORS LLC: 98,950 shares reported 2025-12-31; 91,852 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
28 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Whitehawk Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-04-16 · Giacobello Scott M.: Larger than 80 of the 82 other insider sales of Common Stock on file. SEC filing
- 2026-04-14 · BALL BRYAN: Larger than 74 of the 82 other insider sales of Common Stock on file. SEC filing
- 2026-04-07 · Lennon David James: Larger than 75 of the 82 other insider sales of Common Stock on file. SEC filing
- 2026-04-06 · Lennon David James: Larger than 76 of the 82 other insider sales of Common Stock on file. SEC filing
- 2019-04-26 · NOVARTIS AG: Larger than 78 of the 82 other insider sales of Common Stock on file. SEC filing
- 2019-04-25 · NOVARTIS AG: Larger than all 82 other insider sales of Common Stock on file. SEC filing
- 2019-04-10 · NOVARTIS AG: Larger than 79 of the 82 other insider sales of Common Stock on file. SEC filing
- 2019-04-01 · NOVARTIS AG: Larger than 77 of the 82 other insider sales of Common Stock on file. SEC filing
- 2019-03-26 · NOVARTIS AG: Larger than 81 of the 82 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-04-16 | Giacobello Scott M. · CHIEF FINANCIAL OFFICER | Common Stock | S — Open market or private sale | −141,600 | 4.13 | SEC filing |
| 2026-04-15 | Giacobello Scott M. · CHIEF FINANCIAL OFFICER | Common Stock | S — Open market or private sale | −77,000 | 3.86 | SEC filing |
| 2026-04-14 | BALL BRYAN · See remarks | Common Stock | S — Open market or private sale | −92,460 | 3.64 | SEC filing |
| 2026-04-13 | BALL BRYAN · See remarks | Common Stock | S — Open market or private sale | −26,389 | 3.46 | SEC filing |
| 2026-04-10 | BALL BRYAN · See remarks | Common Stock | S — Open market or private sale | −6,596 | 3.43 | SEC filing |
| 2026-04-09 | Lennon David James · CHIEF EXECUTIVE OFFICER | Common Stock | S — Open market or private sale | −14,500 | 3.38 | SEC filing |
| 2026-04-09 | BALL BRYAN · See remarks | Common Stock | S — Open market or private sale | −50,000 | 3.57 | SEC filing |
| 2026-04-08 | Lennon David James · CHIEF EXECUTIVE OFFICER | Common Stock | S — Open market or private sale | −63,945 | 3.40 | SEC filing |
Showing 8 of 14 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-12 | Maroun Richard E · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +38,040 | SEC filing |
| 2026-06-12 | Castelein Caley · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +38,040 | SEC filing |
| 2026-06-12 | Desai Neil · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +38,040 | SEC filing |
| 2026-06-12 | Reeve Emma · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +38,040 | SEC filing |
| 2026-06-12 | Zhao Baiteng · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +38,040 | SEC filing |
| 2026-06-12 | Avoro Capital Advisors LLC · Director, 10% owner, other | Stock Option (right to buy) | A — Grant, award, or other acquisition | +38,040 | SEC filing |
| 2026-06-12 | Hirmand Mohammad · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +38,040 | SEC filing |
| 2026-05-14 | Dugan Margaret · Chief Medical Officer | Common Stock | A — Grant, award, or other acquisition | +19,132 | SEC filing |
Showing 8 of 21 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.